- $115.72bn
- $134.42bn
- $171.34bn
- 75
- 55
- 80
- 80
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 12.95 | ||
PEG Ratio (f) | 0.62 | ||
EPS Growth (f) | 26.46% | ||
Dividend Yield (f) | 1.28% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.94 | ||
Price to Tang. Book | 31.14 | ||
Price to Free Cashflow | 17.11 | ||
Price to Sales | 0.68 | ||
EV to EBITDA | 12.8 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 8.03% | ||
Return on Equity | 15.85% | ||
Operating Margin | 5.1% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 104,260 | 121,867 | 138,639 | 156,595 | 171,340 | 172,359.65 | 182,408.13 | 13.21% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +31.2 | +7.23 | +27.47 | -4.61 | +14.02 | +34.24 | +11.91 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to Individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. It also offers infusible and injectable therapies. Carelon Services offers healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.
Directors
- Elizabeth Tallett NEC (72)
- Gail Boudreaux PRE (61)
- John Gallina CFO (61)
- Leah Stark CHO (44)
- Gloria McCarthy EVP (68)
- Jeffrey Alter EVP (58)
- Peter Haytaian EVP (51)
- Felicia Norwood EVP (61)
- Prakash Patel EVP (54)
- Blair Todt EVP (53)
- Ronald Penczek SVP (56)
- R. Kerry Clark IND (68)
- Susan DeVore IND
- Robert Dixon IND (65)
- Lewis Hay IND (65)
- Bahija Jallal IND (59)
- Antonio Neri IND (53)
- Ramiro Peru IND (65)
- Ryan Schneider IND (51)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 17th, 2001
- Public Since
- October 30th, 2001
- No. of Shareholders
- 48,679
- No. of Employees
- 104,900
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 232,613,930
- Address
- 220 Virginia Avenue, INDIANAPOLIS, 46204
- Web
- https://www.elevancehealth.com/
- Phone
- +1 3174886000
- Contact
- Stephen Tanal
- Auditors
- Ernst & Young LLP
Upcoming Events for ELV
Q1 2024 Elevance Health Inc Earnings Release
Elevance Health Inc Annual Shareholders Meeting
Elevance Health Inc Annual Shareholders Meeting
Q2 2024 Elevance Health Inc Earnings Release
Similar to ELV
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ati Physical Therapy
New York Stock Exchange
Auna SAA
New York Stock Exchange
FAQ
As of Today at 19:07 UTC, shares in Elevance Health are trading at $497.49. This share price information is delayed by 15 minutes.
Shares in Elevance Health last closed at $497.49 and the price had moved by +0.26% over the past 365 days. In terms of relative price strength the Elevance Health share price has underperformed the S&P500 Index by -19.03% over the past year.
The overall consensus recommendation for Elevance Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Elevance Health dividend yield is 1.19% based on the trailing twelve month period.
Last year, Elevance Health paid a total dividend of $5.92, and it currently has a trailing dividend yield of 1.19%. We do not have any data on when Elevance Health is to next pay dividends.
We do not have data on when Elevance Health is to next pay dividends. The historic dividend yield on Elevance Health shares is currently 1.19%.
To buy shares in Elevance Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $497.49, shares in Elevance Health had a market capitalisation of $115.72bn.
Here are the trading details for Elevance Health:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ELV
Based on an overall assessment of its quality, value and momentum Elevance Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Elevance Health is $578.45. That is 16.27% above the last closing price of $497.49.
Analysts covering Elevance Health currently have a consensus Earnings Per Share (EPS) forecast of $37.16 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Elevance Health. Over the past six months, its share price has underperformed the S&P500 Index by -6.48%.
As of the last closing price of $497.49, shares in Elevance Health were trading +5.37% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Elevance Health PE ratio based on its reported earnings over the past 12 months is 12.95. The shares last closed at $497.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Elevance Health's management team is headed by:
- Elizabeth Tallett - NEC
- Gail Boudreaux - PRE
- John Gallina - CFO
- Leah Stark - CHO
- Gloria McCarthy - EVP
- Jeffrey Alter - EVP
- Peter Haytaian - EVP
- Felicia Norwood - EVP
- Prakash Patel - EVP
- Blair Todt - EVP
- Ronald Penczek - SVP
- R. Kerry Clark - IND
- Susan DeVore - IND
- Robert Dixon - IND
- Lewis Hay - IND
- Bahija Jallal - IND
- Antonio Neri - IND
- Ramiro Peru - IND
- Ryan Schneider - IND